Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2018

Open Access 01-12-2018 | Editorial

The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine

Author: Paolo Martelletti

Published in: The Journal of Headache and Pain | Issue 1/2018

Login to get access

Abstract

Migraine remains one of the biggest clinical case to be solved among the non-communicable diseases, second to low back pain for disability caused as reported by the Global Burden of Disease Study 2016. Despite this, its genetics roots are still unknown. Its evolution in chronic forms hits 2–4% of the population and causes a form so far defined Medication Overuse Headache (MOH), whose pathophysiological basis have not been explained by many dedicated studies. The Global Burden of Disease Study 2016 has not recognized MOH as independent entity, but as a sequela of Chronic Migraine. This concept, already reported in previous studies, has been confirmed by the efficacy of OnabotulinumtoxinA in Chronic Migraine independently from the presence of MOH. The consistency of the current definitions of both Medication Overuse Headache and Chronic Migraine itself might be re-read on the basis of new evidences.
Literature
1.
Negro A, Curto M, Lionetto L, Guerzoni S, Pini LA, Martelletti P (2017) A critical evaluation on MOH current treatments. Curr Treat Options Neurol 19:32CrossRefPubMed
2.
Giamberadino MA, Mitsikostas DD, Martelletti P (2015) Update on medication-overuse headache and its treatment. Curr Treat Options Neurol 17:368
3.
Thorlund K, Sun-Edelstein C, Druyts E et al (2016) Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain 17:107CrossRefPubMedPubMedCentral
4.
5.
Farinelli I, Dionisi I, Martelletti P (2011) Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse? Intern Emerg Med 6:23–28CrossRefPubMed
6.
Negro A, Curto M, Lionetto L, Giamberardino MA, Martelletti P (2016) Chronic migraine treatment: from OnabotulinumtoxinA onwards. Expert Rev Neurother 16:1217–1227CrossRefPubMed
7.
Cevoli S, Giannini G, Favoni V et al (2017) Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. J Headache Pain 18:56CrossRefPubMedPubMedCentral
8.
Davies B, Gaul C, Martelletti P, García-Moncó JC, Brown S (2017) Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain 18:93CrossRefPubMedPubMedCentral
9.
Negro A, Curto M, Lionetto L, Martelletti PA (2015) Two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain 17:1CrossRefPubMed
10.
Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P (2015) OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Spring 4:826CrossRef
11.
Kondratieva N, Azimova J, Skorobogatykh K et al (2016) Biomarkers of migraine: part 1 - genetic markers. J Neurol Sci 369:63–76CrossRefPubMed
12.
Cargnin S, Pautasso C, Viana M et al (2015) Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache. Headache 55:658–668CrossRefPubMed
13.
Cargnin S, Viana M, Sances G et al (2014) Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. Eur J Clin Pharmacol 70:1195–1202CrossRefPubMed
14.
Cargnin S, Viana M, Ghiotto N et al (2014) Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. Eur J Neurol 21:989–995CrossRefPubMed
15.
Gentile G, Borro M, Simmaco M, Missori S, Martelletti P. Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Exp Opin Drug Metab Toxicology 2011;7:39-47
16.
Chen Z, Chen X, Liu M, Dong Z, Ma L, Altered YS (2017) Functional connectivity architecture of the brain in medication overuse headache using resting state fMRI. J Headache Pain 18:25CrossRefPubMedPubMedCentral
17.
Chen Z, Chen X, Liu M, Liu S, Ma L, Texture YS (2017) Features of periaqueductal gray in the patients with medication-overuse headache. J Headache Pain 18:14CrossRefPubMedPubMedCentral
18.
19.
Giamberardino MA, Martelletti P (2017) In: Martelletti P (ed) Comorbitidies in headache disorders. Springer International Publishing, Switzerland, pp 1–217CrossRef
20.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 390:1211–1259CrossRef
21.
Martelletti P (2017) The application of CGRP(r) monoclonal antibodies in migraine spectrum: needs and priorities. BioDrugs 31:483–485CrossRefPubMed
22.
Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, Buse DC (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18:101CrossRefPubMedPubMedCentral
23.
Lionetto L, Borro M, Curto M et al (2016) Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic consideration. Exp Opin Drug Metab. Toxicology 12:399–406
24.
25.
Borro M, Gentile G, Cipolloni L et al (2017) Personalized healthcare: the DiMA clinical model. Current Pharmaceutical Biothechnology 18:242–252CrossRef
26.
Simmaco M, Borro M, Missori S, Martelletti P (2009) Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Expert Rev Neurother 9:1267–1269CrossRefPubMed
27.
Metadata
Title
The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine
Author
Paolo Martelletti
Publication date
01-12-2018
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2018
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-017-0830-2

Other articles of this Issue 1/2018

The Journal of Headache and Pain 1/2018 Go to the issue

Research article

Use and overuse of triptans in Austria – a survey based on nationwide healthcare claims data

Research article

Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0 T

Research article

Effects of topical vs injection treatment of cervical myofascial trigger points on headache symptoms in migraine patients: a retrospective analysis

Research article

PKM2 is involved in neuropathic pain by regulating ERK and STAT3 activation in rat spinal cord

Review article

PACAP in hypothalamic regulation of sleep and circadian rhythm: importance for headache

Research article

Exploration of intrinsic brain activity in migraine with and without comorbid depression